New England Journal of Medicine July 02, 2015

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C.W. Lau, Carel W. le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen, John P.H. Wilding

Source: View publication →

Bottom Line

Liraglutide 3.0 mg, combined with lifestyle modifications, safely and effectively induces significant weight loss and improves metabolic control in non-diabetic overweight and obese patients compared to placebo.

Key Findings

1. At week 56, patients in the liraglutide 3.0 mg group lost a mean of 8.4 ± 7.3 kg of body weight, compared to 2.8 ± 6.5 kg in the placebo group (a difference of -5.6 kg; 95% CI, -6.0 to -5.1; P<0.001) [2.1.1].

2. 63.2% of patients treated with liraglutide achieved at least 5% body weight loss, compared to 27.1% in the placebo group (P<0.001).

3. 33.1% of patients treated with liraglutide achieved more than 10% body weight loss, compared to 10.6% in the placebo group (P<0.001).

4. The most frequently reported adverse events with liraglutide were mild or moderate nausea and diarrhea.

5. Serious adverse events occurred in 6.2% of the patients in the liraglutide group and 5.0% of the patients in the placebo group.

Study Design

Design

Randomized Controlled Trial

Double-Blind

Sample

3,731

Patients

Duration

56 wk

Median

Setting

Multicenter, Global

Population Adults without type 2 diabetes with a body-mass index (BMI) of at least 30, or a BMI of at least 27 with treated or untreated dyslipidemia or hypertension.

Intervention Once-daily subcutaneous injections of liraglutide 3.0 mg, combined with counseling on lifestyle modification.

Comparator Once-daily subcutaneous injections of placebo, combined with counseling on lifestyle modification.

Outcome Co-primary endpoints: The change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight at week 56.

Study Limitations

• High incidence of gastrointestinal adverse events, particularly nausea and vomiting, which led to treatment discontinuation in a subset of patients [3.1.1].

• The 56-week duration of the primary analysis phase was not long enough to establish definitive long-term cardiovascular safety or mortality outcomes.

• The intensive behavioral intervention (counseling and a 500 kcal/day deficit diet) utilized in the clinical trial setting may be difficult to replicate and maintain in routine real-world clinical practice.

• The study specifically excluded patients with type 2 diabetes, requiring a separate trial (SCALE Diabetes) to assess efficacy and safety in that population.

Clinical Significance

The SCALE Obesity and Prediabetes trial established the efficacy and safety of high-dose liraglutide (3.0 mg) for chronic weight management. By demonstrating substantial, clinically meaningful weight loss and improved metabolic parameters in non-diabetic patients, it provided strong foundational evidence for the FDA approval of Saxenda. This trial helped catalyze a paradigm shift, recognizing obesity as a chronic disease manageable by incretin-based neurohormonal therapies.

Historical Context

Prior to this trial, pharmacological options for obesity were limited, often hindered by modest efficacy or concerning neuropsychiatric and cardiovascular safety profiles (e.g., sibutramine, rimonabant). Liraglutide, initially approved at a lower 1.8 mg dose for type 2 diabetes (Victoza), was known to cause secondary weight loss. The SCALE clinical trial program purposefully investigated a higher 3.0 mg dose specifically for obesity, leading to its landmark approval as the first once-daily GLP-1 receptor agonist indicated for chronic weight management.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does a GLP-1 receptor agonist like liraglutide physiologically induce weight loss in non-diabetic patients?

Key Response

This question tests foundational knowledge of incretin physiology, specifically focusing on the drug's central effects on satiety and hunger centers in the hypothalamus, as well as peripheral effects like delayed gastric emptying, which are distinct from its glucose-dependent insulinotropic effects.

Resident

Based on the SCALE trial's safety profile, what are the most common adverse effects of liraglutide 3.0 mg that require patient counseling and dose titration, and what are its absolute endocrinologic contraindications?

Key Response

Residents must know how to practically manage the dose-dependent gastrointestinal side effects (nausea, vomiting, diarrhea) through proper dose titration, and they must screen for absolute contraindications such as a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Fellow

The SCALE trial included a large sub-cohort of patients with prediabetes. How does liraglutide 3.0 mg alter the natural history of progression to Type 2 Diabetes in this specific subgroup, and what are the metabolic consequences upon cessation of the medication?

Key Response

Fellows should grasp nuanced long-term metabolic outcomes. While liraglutide effectively delays diabetes onset and often reverts prediabetes to normoglycemia during active use, cessation typically leads to rapid weight regain and a reversion of these metabolic benefits, underscoring obesity as a chronic disease requiring indefinite pharmacotherapy.

Attending

How does the requirement of chronic daily injections for sustained weight loss challenge the traditional 'lifestyle-first' paradigm of obesity management, and how can clinicians mitigate the high real-world discontinuation rates seen outside of heavily monitored clinical trials?

Key Response

Attendings must deal with the practical realities of prescribing: managing costs, prior authorizations, long-term adherence to injectables, and facilitating a paradigm shift for both patients and peers to treat obesity as a chronic, relapsing neuroendocrine disease rather than a behavioral willpower deficit.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

In long-term obesity trials like SCALE, attrition rates are notoriously high due to adverse events or lack of perceived efficacy. How does the trial's specific statistical handling of missing data potentially bias the estimate of the treatment effect, and what modern estimands are preferred by regulatory agencies today?

Key Response

This challenges researchers to critically evaluate how data missingness can artificially inflate or deflate weight loss estimates if not handled via rigorous methods like mixed models for repeated measures (MMRM) or specific FDA-recommended estimands, distinguishing between treatment-policy and efficacy estimands.

Journal Editor

How does the distinct side effect profile of liraglutide, specifically the disproportionately high rates of early nausea, threaten the integrity of the double-blind design in the SCALE trial, and could this functional unblinding introduce performance bias regarding the concurrent lifestyle intervention?

Key Response

An editor must evaluate threats to internal validity. If patients in the active arm infer their group assignment due to unmistakable gastrointestinal effects, they may exhibit higher motivation and adherence to the concurrent lifestyle and diet intervention, thereby introducing performance bias and confounding the drug's true isolated effect.

Guideline Committee

Given the robust cardiometabolic improvements and weight loss seen in the SCALE trial, should current clinical practice guidelines elevate GLP-1 receptor agonists to preferred first-line pharmacotherapy over older oral agents for patients with a BMI over 30, and how should cost-effectiveness and route of administration temper the strength of this recommendation?

Key Response

Guideline developers must explicitly weigh the superior efficacy and cardiometabolic profile of GLP-1 RAs against their high cost and injectable delivery when positioning them versus older, cheaper oral agents (like phentermine/topiramate) in algorithms such as the AACE/ACE or AHA/ACC/TOS obesity management guidelines.

Clinical Landscape

Noteworthy Related Trials

2016

LEADER Trial

n = 9,340 · NEJM

Tested

Liraglutide 1.8 mg daily

Population

Patients with type 2 diabetes and high cardiovascular risk

Comparator

Placebo

Endpoint

3-point MACE

Key result: Liraglutide significantly reduced the risk of the primary composite cardiovascular outcome and death from any cause.

2021

STEP 1 Trial

n = 1,961 · NEJM

Tested

Semaglutide 2.4 mg once weekly

Population

Adults with obesity or overweight without diabetes

Comparator

Placebo

Endpoint

Percentage change in body weight at week 68

Key result: Semaglutide achieved a mean weight loss of 14.9% compared to 2.4% with placebo.

2022

SURMOUNT-1 Trial

n = 2,539 · NEJM

Tested

Tirzepatide 5 mg, 10 mg, or 15 mg once weekly

Population

Adults with obesity or overweight without diabetes

Comparator

Placebo

Endpoint

Percentage change in body weight at week 72

Key result: Tirzepatide provided substantial weight reduction, with a mean change of -20.9% at the highest dose compared to -3.1% for placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis